Amicus Therapeutics Inc

Amicus Therapeutics — Investor Presentation (May 2019)

47 slides from Amicus Therapeutics's investor presentation, May 14, 2019

  1. Slide 1: Amicus Therapeutics' Corporate Overview May 2019

    Amicus Therapeutics’ Corporate Overview May 2019

  2. Slide 2: Forward-Looking Statements

    2 Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of our product candidates, the timing and reporting of results from preclinical studies and

  3. Slide 3: Amicus Highlights

    Introduction 3 Amicus Highlights GALAFOLD’S EXTRAORDINARY LAUNCH AT-GAA IN POMPE: POTENTIAL TO LEADING GENE THERAPY PORTFOLIO IN RARE SUCCESS BECOME STANDARD OF CARE METABOLIC DISEASES • 650+ Patients and $91.2M Global Sales in FY18 • Continued Strength of Clinical Data • Pipeline of 14 Gene Therapi

  4. Slide 4: Amicus Founding Beliefs

    Introduction 4 Amicus Founding Beliefs WE BELIEVE... WE BELIEVE... WE BELIEVE… In the Fight to Remain In Our Future to Build In Each Other to at the ForefrontWe push of ideas as Longfar-term and Value as for fast as possibleFoster Teamwork and Therapies for Rare and Our Stakeholders Respect for Each

  5. Slide 5: Amicus portfolio, platform and global footprint

    Introduction 5 PORTFOLIO 500+ of 15 programs for rare EMPLOYEES metabolic diseases globally BIOLOGICS AT-GAA* PLATFORM Phase 3 Leading Expertise in Protein Engineering Investigational Lysosomal & Glycobiology Therapy for Pompe Storage GLOBAL Disorders $500M+ Gene Therapy FOOTPRINT Cash in 27 countri

  6. Slide 6: Rare disease pipeline by franchise

    Introduction 6 DISCOVERY PRECLINICAL PHASE 1/2 PHASE 3 REGULATORY COMMERCIAL Fabry Franchise Galafold®(migalastat) monotherapy Fabry Gene Therapy PENN Pompe Franchise AT-GAA (Novel ERT + Chaperone) Pompe Gene Therapy PENN Batten Franchise – Gene Therapies NCH CLN6 Batten Disease Advancing one NCH CL

  7. Slide 7: Key Drivers of Value

    Introduction 7 Key Drivers of Value Pompe Gene Galafold ERT Therapy $1B+ $1B-2B+ Portfolio Opportunity Opportunity $1B+ Opportunity Transformthe Lives of Thousands of Patients

  8. Slide 8: 2019 Key Strategic Priorities

    Introduction 8 2019 Key Strategic Priorities 1 Nearly double annual revenue for Galafold (guidance $160M-$180M) Complete enrollment in AT-GAA Pivotal Study (PROPEL) and 2 report additional Phase 1/2 data Report additional 2-year clinical results in CLN6-Batten disease and 3 complete enrollment in on

  9. Slide 9: Impacting Lives

    Introduction 9 Impacting Lives >350 Patients* | ~$36M Global Sales >700 Patients* | ~$91M1 Global Sales 5,000 Patients* | $1B Global Sales YE17 YE18 2023 *Clinical & commercial, all figures approximate 1Preliminary unaudited

  10. Slide 10: Amicus in 2023

    Introduction 10 Amicus in 2023 Our Path to Become One of the Leading Global Biotechnology Companies in Rare Diseases ~$1B / ~5,000 patients in 2023 Gene Therapies & In- Galafold AT-GAA* Approved licensed Products* ~$500M ~$200M ~$300M Clinical 5+ Programs in Clinic Preclinical 1+ New IND Every 12-18

  11. Slide 11: Fabry Disease Overview

    Fabry Disease Overview “We support the disease communities – and their families” - Amicus Belief Statement

  12. Slide 12: Fabry Disease Overview

    Fabry Disease 12 Fabry Disease Overview Fabry Disease is a Fatal Leading Causes of Death: Genetic Disorder that Affects Transient Ischemic Attack Multiple Organs and is (TIA) & Stroke1 Believed to be Significantly Underdiagnosed Heart Disease2 Kidney Disease3 Key Facts: • α-Gal A enzyme deficiency l

  13. Slide 13: Global Fabry Market Growth Driven by New Patients

    Fabry Disease 13 Global Fabry Market Growth Driven by New Patients Global Fabry Market Exceeded $1.4B as of 3Q18 and Tracking Toward $2.2B by 2023 (8.6% 5-Year CAGR)* Annualized 3Q18 Fabry sales increased $2,500 10% $2,000 $1,500 Japan ROW 15% 20% (millions) $1,000 EU 34% U.S. $500 31% $0 2015 2016

  14. Slide 14: Fabry Underdiagnosis

    Fabry Disease 14 Fabry Underdiagnosis Newborn Screening Studies Suggests Fabry Could Be One of the More Prevalent Human Genetic Diseases NEWBORN 8454ENING STUDY NEWBORNS SCREENED CONFIRMED FABRY MUTATIONS % AMENABLE Index 15 Patient Hopkins, 2018, Missouri, US 43,701 N/A [1:~2913] 26 Burton, 2017, I

  15. Slide 15: Fabry Misdiagnosis

    Fabry Disease 15 Fabry Misdiagnosis Recent Studies in Multiple Disease Areas Show Significant Rate of Fabry Disease as Underlying Cause 36,820 # Patients Screened Patients # 5,978 5,491 3,074 2,360 361 273 88 6.8 5.5 Diagnosed Diagnosed withFabry % % 1.3 0.8 0.5 0.5 0.6 0.3 Renal: CV: CV: Renal: Spe

  16. Slide 16: Galafold (migalastat) Global Launch

    Galafold® (migalastat) Global Launch… …taking a leadership role in the treatment of Fabry disease “We push ideas as far and as fast as possible” - Amicus Belief Statement

  17. Slide 17: Galafold: Precision Medicine for Fabry Disease

    Galafold: Precision Medicine for Fabry Disease 17 Galafold Snapshot (as of March 31, 2019) $34.0M $160-180M One of the Most 1Q19 Galafold FY19 Global Revenue Galafold Successful Rare Rev. Guidance Disease Launches Geographic 24 Countries with Expansion in Pricing & 2019 Reimbursement 8 Regulatory 34

  18. Slide 18: Galafold Global Launch Momentum

    18 Galafold Global Launch Momentum (as of March 31, 2019) Q1 was very strong with largest number of net new patient adds (150+) and positive momentum across all key commercial metrics . Global: 150+ new patient adds with continued >90% compliance and adherence. Now estimate ~18% global market share

  19. Slide 19: Galafold Quarterly Performance

    Galafold: Precision Medicine for Fabry Disease 19 Galafold Quarterly Performance 1Q19 Revenue of $34.0M Grew 104% Year-over-Year Reflecting Continued Strong Growth in Global Adoption of First Fabry Oral Precision Medicine • 1Q19 in-line with management $34.0M $32.6M expectations • Consistent with Ga

  20. Slide 20: Galafold Success and FY19 Revenue Guidance

    Galafold: Precision Medicine for Fabry Disease 20 Galafold Success and FY19 Galafold Revenue Guidance On Track to Nearly DOUBLE Revenue Again and Serve 1,000+ Patients in 2019 $160M-180M Guidance $91.2M $32.6M $36.9M $20.6M $80$21.3M-90M $4.9M $16.7M FY16 FY17 FY18 FY19

  21. Slide 21: Upside Potential: Total Amenable Patient Population

    Galafold: Precision Medicine for Fabry Disease 21 Upside Potential Total Amenable Patient Population (“TAPP”) WORLDWIDE Estimate based on 35% - 50% amenability Diagnosis grows due to newborn screening and patient finding initiatives in U.S. & Japan $1B+ Addressable Market TAPP: 4,700-6,750 Peak Pote

  22. Slide 22: AT-GAA Novel ERT for Pompe Disease

    AT-GAA Novel ERT for Pompe Disease “We encourage and embrace constant innovation” - Amicus Belief Statement

  23. Slide 23: Pompe Disease Overview

    AT-GAA for Pompe Disease 23 Pompe Disease Overview Pompe Disease is a Fatal Neuromuscular Disorder that Affects a Broad Range of People Respiratory and cardiac 5,000 – 10,000 patients Age of onset ranges from infancy to failure are leading causes of morbidity diagnosed WW1 adulthood and mortality De

  24. Slide 24: AT-GAA: A Differentiated Treatment Paradigm

    AT-GAA for Pompe Disease 24 AT-GAA (ATB200 + Chaperone): A Differentiated Treatment Paradigm

  25. Slide 25: Pompe Patient Experience in Phase 1/2 Clinical Study

    AT-GAA for Pompe Disease 25 Pompe Patient Experience in Phase 1/2 Clinical Study (ATB200-02) Consistent and Durable Responses Across Key Measures of Safety, Functional Outcomes and Biomarkers in both ERT-Switch and ERT-Naïve Pompe Patients out to Month 18 6-Minute Walk Test (m) Change at Month 24a,b

  26. Slide 26: AT-GAA: Breakthrough Therapy Designation

    AT-GAA for Pompe Disease 26 AT-GAA: Breakthrough Therapy Designation U.S. FDA Granted BTD to AT-GAA in Late-Onset Pompe Disease (LOPD) BTD Criteria • Intended to treat a serious or life threatening disease or condition • Preliminary clinical evidence indicates drug may demonstrate substantial improv

  27. Slide 27: PROPEL (ATB200-03) Study Design

    AT-GAA for Pompe Disease 27 PROPEL (ATB200-03) Study Design 52-Week Primary Treatment Period Long-Term Extension (Double-Blind) (Open-Label) Participants with Late-Onset AT-GAA Pompe Disease Bi-Weekly ~100 Patients AT-GAA 90 Clinical Sites Worldwide Bi-weekly Standard of Care ERT-Switch ERT-Naïve Bi

  28. Slide 28: Pompe Biologics Manufacturing

    AT-GAA for Pompe Disease 28 Pompe Biologics Manufacturing Successful Scale Up to 1000L GMP Clinical and Commercial Scale to Fully Supply Global Pompe Population • Key quality attributes maintained from 5L to 250L to 1000L • Agreements on biocomparability with key regulators (FDA, BfARM) • PROPEL par

  29. Slide 29: AT-GAA: 2019 Objectives

    AT-GAA for Pompe Disease 29 AT-GAA: 2019 Objectives Advance AT-GAA for as Many Patients Worldwide as Quickly as Possible  Additional Phase 1/2 Data (up to 24 Months)  Breakthrough Therapy Designation  Full enrollment of Phase 1/2 Study (Cohorts 1-4) • Full enrollment of PROPEL study (n=100) • Pre

  30. Slide 30: Gene Therapy Pipeline

    Gene Therapy Pipeline “We have a duty to obsolete our own technologies” - Amicus Belief Statement

  31. Slide 31: Amicus Gene Therapy Programs

    Amicus Gene Therapy Programs 31 Leading Lysosomal Disorder Gene Therapy Portfolio Multiple Platforms Provide 14 Gene Therapy Programs and R&D Engine for Future Growth Gene Therapy Program Updates Positive initial preclinical data for Pompe gene therapy CLN3 Batten Disease Phase 1/2 Study Enrolling;

  32. Slide 32: Addressable Patient Populations in Neurologic LSDs

    Amicus Gene Therapy Programs 32 Addressable Patient Populations in Neurologic LSDs* 10,000+ Addressable Patients in 10 Indications $1B+ Annual Recurring Revenue >3,500 Niemann-Pick, Wolman Disease, ~750 Tay-Sachs, and CLN8 Others ~5,000 ~1,000 CLN3 CLN6 *Estimated addressable U.S., EU, Japan, and ot

  33. Slide 33: AAV9-CLN6 Efficacy Data: Matched Sibling Case Report

    AAV9-CLN6 Gene Therapy for CLN6-Batten Disease 33 Efficacy Data: Matched Sibling Case Report Encouraging Interim Efficacy Data in First Two Patients Treated with Gene Therapy with Two Years of Follow-up Normal • Two siblings (same genotype) function 6 GTx dosing treated with gene therapy at ages You

  34. Slide 34: Protein Engineering Expertise for Gene Therapy

    Amicus Gene Therapy Programs 34 Amicus Protein Engineering Expertise & Technologies for Gene Therapy Collaboration to Enable Greater Protein Expression and Delivery at Lower Gene Therapy Doses Increased Increased Improved Protein Protein Protein Targeting & Expression Secretion Stabilization Novel u

  35. Slide 35: Early Proof of Principle for Optimized Gene Therapy

    Amicus Gene Therapy Programs 35 Early Proof of Principle for Optimized Gene Therapy Amicus DNA Constructs Enable Optimized Gene Therapy in Pompe and Fabry GAA Binding to Intended Receptor SecretedS e c re te d GAArh G A Ain i nMedia M e d ia 8 0 0 0 y t 8 0 A m ic u s G T - G A A i ) v i ) r y t r W

  36. Slide 36: Preclinical Pompe Gene Therapy Results

    Preclinical Pompe Gene Therapy Results 36 Preclinical Pompe Gene Therapy Results Presented at ASGCT Initial Findings Validate Amicus/Penn Collaboration Combining Amicus-Engineered Transgenes with Penn’s AAV Gene Therapy Technologies Key findings: • Improved cellular uptake and glycogen reduction obs

  37. Slide 37: Manufacturing: Three-Pronged Approach

    Amicus Gene Therapy Programs 37 Manufacturing: Three-Pronged Approach Proven Amicus Track Record Long in Biologics Manufacturing Term Applies to Gene Therapy Mid Term Now Amicus manufacturing NCH and UPenn to supply initial clinical studies GMP clinical supply available for ongoing studies at NCH Fi

  38. Slide 38: Financial Summary & Milestones

    Financial Summary & Milestones “We have a duty to obsolete our own technologies” - Amicus Belief Statement

  39. Slide 39: Financial Summary and Guidance

    Financial Summary 39 Financial Summary and Guidance Strong Balance Sheet with $435M+ Cash at 3/31/19- Cash Runway into 2021 FINANCIAL POSITION March 31, 2019 Cash ~$438M Cash Runway Into at least mid-2021 CAPITALIZATION Shares Outstanding 230,180,714 FINANCIAL GUIDANCE Projected YE 2019 Cash Balance

  40. Slide 40: Anticipated Milestones: 2019

    Upcoming Milestones 40 Anticipated Milestones: 2019 Well-Positioned to Create Significant Value for Patients and Shareholders in 2019 Galafold: Fabry Disease AT-GAA: Pompe Disease Gene Therapy Programs  • FY19 revenue guidance $160M- Additional Phase 1/2 data (21 and 24 • Ongoing CLN3 Batten diseas

  41. Slide 41: Thank You

    Thank You “Our passion for making a difference unites us” -Amicus Belief Statement

  42. Slide 42: Appendix

    Appendix

  43. Slide 43: AAV Gene Therapy Initial High-Dose Preclinical POC Study

    Preclinical Pompe Gene Therapy Results at ASGCT 43 AAV Gene Therapy Initial High-Dose Preclinical POC Study • AAV Transgene: AAV Expressing Trans-Gene Co nstructs – Natural-hGAA (AAV.hGAA nat) – Engineered-hGAA (AAV.hGAA eng) Native Signal Peptide Natural hGAA • Dose\Route: – 5e11 gc/mouse (~2.5e13

  44. Slide 44: GAA Plasma Activity, Concentration and Receptor Binding

    Preclinical Pompe Gene Therapy Results at ASGCT 44 GAA Plasma Activity, Concentration and Cell-Surface Receptor Binding Binding to Intended Receptor Day 28 Plasma Samples used to evaluate receptor binding • Engineered hGAA was able to efficiently bind the • High levels of engineered and natural hGAA

  45. Slide 45: Tibialis Anterior – 28 days after AAV Gene Therapy

    Preclinical Pompe Gene Therapy Results at ASGCT 45 Tibialis Anterior – 28 days after AAV Gene Therapy Engineered hGAA was more Efficient at Cross-Correction as Indicated by Greater Cellular Uptake, Uniform Glycogen Reduction and Cell Pathology Correction Glycogen PAS - Tibialis anterior Vehicle AAV.

  46. Slide 46: Brain – days after AAV Gene Therapy

    Preclinical Pompe Gene Therapy Results at ASGCT 46 Brain– 28 days after AAV Gene Therapy Engineered hGAA was able to Cross-Correct the Brain at Low Levels Due to Efficient Cellular Uptake while Natural hGAA was not able to Cross-Correct at Similar Expression Levels Glycogen Luxol/PAS - Brain Vehicle

  47. Slide 47: Spinal Cord – 28 days after AAV Gene Therapy

    Preclinical Pompe Gene Therapy Results at ASGCT 47 Spinal Cord– 28 days after AAV Gene Therapy Engineered hGAA was able to Reduce Glycogen Efficiently in the Spinal Cord while Little GGlycogenlycogen Luxo Reductionl/PAS – Spinal Cwasord Observed for Natural Vehicle AAV.hGAA nat AAV.hGAA eng Wild-Typ

Amicus Therapeutics — Investor Presentation (May 2019) on 6ix